Ceftriaxone was able to successfully eliminate the cellular toxic effects of misfolded glial fibrillary acid protein (GFAP) in a cellular model of Alexander’s disease [25] as well as to protect dopaminergic neurons ameliorating motor deficits in a rat model of Parkinson’s disease [26]. This evidence concerns the gene GFAP and Alexander disease.